Dr. Clay Siegall presents the brains behind Seattle Genetics, a leading Seattle biotech giant, which he founded in 1998. This Company deals with research and development of innovative therapy drugs for diseases, mainly cancer. As the CEO, he has been the major source of influence in the firm’s rise within the targeted therapy drugs landscape. Seattle Genetics is an approved entity and was given the green light by the FDA to develop the innovative antibody-drug conjugates. Seattle Genetics has developed 20 other drugs and has fostered working partnerships with reputable manufacturers including Bayer, Genentech, and Pfizer.
Under the leadership of Clay Siegall, Seattle Genetics isn’t the same startup it was some years back. Dr. Siegall has managed to transform the company that started with a few researchers into the absolute powerhouse it has become in the cancer research and drug development arena. Dr. Siegall was always mesmerized by medicine and modern technology. His quest was to innovate and provide solutions to affected individuals. He was motivated by the need to provide superior treatment methods away from the crude options that existed. Equally, Dr. Siegall wanted to enjoy autonomy and the benefits that his patents would bring along.
Seattle Genetics runs like any other prescription drug business. After the FDA approved their ADC drugs, they started to realize significant profits. Again, the company has stable revenue streams arising from the partnerships they have with other players. The biotech firm makes money from patents and licensed technologies that they have developed. Even with the drugs approved, it wasn’t a walk in the park to find clients and realize steady profits. Clay had to employ his competence and business acumen to help Seattle Genetics to roll out a successful IPO.
The success of the biotech firm can be traced back to Dr. Siegall’s sharp focus to succeed in the cancer research niche. His years of experience since his youthful years at the University of Maryland and George Washington University seem to have borne fruits. He is an accomplished zoologist, top genetic researcher, and an author who is unstoppable on his mission to find a lasting solution to challenges faced by cancer patients. He sits on the boards of health and research bodies including Mirna Therapeutics, Alder Biopharmaceuticals, and Ultragenyx Pharmaceutical.